1.Development of a Checklist for the Detection of Lipohypertrophy at Insulin Injection Sites.
Myeonghee HONG ; Yanghee KIM ; Kyungho LIM
Journal of Korean Diabetes 2016;17(2):106-111
Lipohypertrophy refers to the phenomenon of subcutaneous fatty tissue becoming either softer or firmer than normal so that it becomes thickened. The presence of lipohypertrophy is associated with not rotating injection sites correctly, injecting into the same sites repeatedly, using smaller injection zones, and reusing needles. Injecting into lipohypertrophy sites can cause unexplained hypoglycemia because insulin absorption is delayed or erratic, thus potentially worsening glucose levels and even diabetes management. Therefore, developing a lipohypertrophy checklist for patients who inject insulin is necessary to detect lipohypertrophy as soon as possible in order to avoid repeatedly injecting into lipohypertrophy sites. A lipohypertrophy checklist will help patients maintain stable glucose levels by minimizing the risk of glycemic variability.
Absorption
;
Adipose Tissue
;
Checklist*
;
Glucose
;
Humans
;
Hypoglycemia
;
Insulin*
;
Needles
2.A Placebo-Controlled, Single and Multiple Dose Study to Investigate the Appropriate Parameters for Evaluation of Pharmacodynamic Equivalence of Voglibose in Healthy Korean Volunteers.
Kyungho JANG ; Sang Heon CHO ; Jung Ryul KIM ; Jae Yong CHUNG ; Kyoung Soo LIM ; In Jin JANG ; Kyung Sang YU
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2013;21(1):63-70
BACKGROUND: Voglibose is an alpha-glucosidase inhibitor. The purpose of this study was to evaluate the pharmacodynamic characteristics of voglibose for determining the appropriate study design and parameters for a pharmacodynamic equivalence study of voglibose. METHODS: This study consisted of two studies. The single dose study had an open and single sequence design. Nineteen subjects received placebo and then one tablet of voglibose on two consecutive days with sucrose. The multiple dose study was performed with the similar design, except that it was a multiple dose of the single dose study. Nine subjects who showed an effective response in the single dose study received placebo three times and then voglibose 4 times on two consecutive days. Serial blood samples for pharmacodynamic parameters were taken until 180 mins after each administration. The baseline adjusted maximum serum glucose level (G(max)) and area under the serum glucose level-time profiles were determined and compared. RESULTS: In the single dose study, the difference in G(max) was -10.6 +/- 28.7 mg/dL. The area under the serum glucose concentration-time curve (AUGC(0-1h)) of placebo and voglibose were 7825.0 +/- 1145.3 mg.min/dL, 7907.5 +/- 917.2 mg.min/dL, respectively. In the multiple dose study, the difference in G(max) was 46.6 +/- 16.1 mg/dL. The AUGC(0-1h) of placebo and voglibose were 8138.6 +/- 721.9 mg.min/dL and 6499.7 +/- 447.2 mg.min/dL, respectively. The G(max) and AUGC(0-1h) of the multiple dose study was significantly different between placebo and voglibose in paired t-test. CONCLUSION: The differences in G(max) and AUGC(0-1h) are suitable for pharmacodynamic parameters to evaluate bioequivalence of voglibose.
alpha-Glucosidases
;
Glucose
;
Inositol
;
Sucrose
;
Therapeutic Equivalency
3.Aquatide Activation of SIRT1 Reduces Cellular Senescence through a SIRT1-FOXO1-Autophagy Axis.
Chae Jin LIM ; Yong Moon LEE ; Seung Goo KANG ; Hyung W LIM ; Kyong Oh SHIN ; Se Kyoo JEONG ; Yang Hoon HUH ; Suin CHOI ; Myungho KOR ; Ho Seong SEO ; Byeong Deog PARK ; Keedon PARK ; Jeong Keun AHN ; Yoshikazu UCHIDA ; Kyungho PARK
Biomolecules & Therapeutics 2017;25(5):511-518
Ultraviolet (UV) irradiation is a relevant environment factor to induce cellular senescence and photoaging. Both autophagy- and silent information regulator T1 (SIRT1)-dependent pathways are critical cellular processes of not only maintaining normal cellular functions, but also protecting cellular senescence in skin exposed to UV irradiation. In the present studies, we investigated whether modulation of autophagy induction using a novel synthetic SIRT1 activator, heptasodium hexacarboxymethyl dipeptide-12 (named as Aquatide), suppresses the UVB irradiation-induced skin aging. Treatment with Aquatide directly activates SIRT1 and stimulates autophagy induction in cultured human dermal fibroblasts. Next, we found that Aquatide-mediated activation of SIRT1 increases autophagy induction via deacetylation of forkhead box class O (FOXO) 1. Finally, UVB irradiation-induced cellular senescence measured by SA-β-gal staining was significantly decreased in cells treated with Aquatide in parallel to occurring SIRT1 activation-dependent autophagy. Together, Aquatide modulates autophagy through SIRT1 activation, contributing to suppression of skin aging caused by UV irradiation.
Autophagy
;
Cell Aging*
;
Fibroblasts
;
Humans
;
Skin
;
Skin Aging
4.Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Associated Disease in Korean Children
Il Han YOO ; WooJoong KIM ; Youngkyu SHIM ; Sun Ah CHOI ; Soo Yeon KIM ; Hunmin KIM ; Byung Chan LIM ; Hee HWANG ; Jieun CHOI ; Ki Joong KIM ; Yeseul KIM ; Jae-Won HYUN ; Su-Hyun KIM ; Kyungho CHOI ; Ho Jin KIM ; Jong-Hee CHAE
Journal of Clinical Neurology 2020;16(3):461-469
Background:
and Purpose: The myelin oligodendrocyte glycoprotein (MOG) antibody is detected at a high rate in childhood acquired demyelinating syndrome (ADS). This study aimed to determine the diagnostic value of the MOG antibody in ADS and the spectrum of MOGantibody-positive demyelinating diseases in children.
Methods:
This study included 128 patients diagnosed with ADS (n=94) or unexplained encephalitis (n=34). The MOG antibody in serum was tested using an in-house live-cell-based immunofluorescence assay.
Results:
The MOG antibody was detected in 48 patients (46 ADS patients and 2 encephalitis patients, comprising 23 males and 25 females). Acute disseminated encephalomyelitis (ADEM) (35.4%) was the most-common diagnosis, followed by the unclassified form (17.4%), isolated optic neuritis (ON) (15.2%), neuromyelitis optica spectrum disorder (13.0%), multiple sclerosis (MS) (10.8%), other clinically isolated syndromes [monophasic event except ADEM, isolated ON, or transverse myelitis (TM)] (8.7%), and unexplained encephalitis (4.3%). At the initial presentation, 35 out of the 46 patients with ADS had brain lesions detected in magnetic resonance imaging, and 54% of these 35 patients had encephalopathy. Nine of the 11 patients without brain lesions exhibited only ON. Thirty-nine percent of the patients experienced a multiphasic event during the mean follow-up period of 34.9 months (range 1.4–169.0 months). Encephalopathy at the initial presentation was frequently confirmed in the monophasic group (p= 0.011).
Conclusions
MOG antibodies were identified in all pediatric ADS phenotypes except for monophasic TM. Therefore, the MOG antibody test is recommended for all pediatric patients with ADS, especially before a diagnosis of MS and for patients without a clear diagnosis.